Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pascal Soriot

Soriot should explain the curious case of AstraZeneca’s non-deal

AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders

The Guardian - UK

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling

The Guardian - UK

AstraZeneca falls to third-largest UK company amid US merger talks

Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca boss urges western drugmakers to move at ‘Chinese speed’

Europe and US risk being outpaced on innovation, as happened in the car industry, warns Pascal Soriot

The Guardian - UK

AstraZeneca quarterly net profit rises 2% on strong cancer drug sales

Strong cancer drug sales lifted Anglo-Swedish pharmaceutical giant AstraZeneca’s second-quarter earnings above expectations, helping the company maintain its 2026 outlook.

Euronews

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company…

The Economic Times

Pay gap widens as UK bosses get 130 times average worker’s salary

In its final report the High Pay Centre says the median remuneration of a FTSE 100 CEO has risen to a record £5.06m

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca to inject £300 million into UK in surprise U-turn

AstraZeneca chief executive Pascal Soriot has thanked the Government ‘for their efforts to improve access for patients’

The Independent UK

AstraZeneca makes surprise U-turn with £300m pharma investment in UK

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer

The Guardian - UK

AstraZeneca boss Pascal Soriot nets £17.7m in pay and bonuses for 2025

The drug maker’s annual report showed his total pay lifted 6.4% last year after he was awarded nearly £16 million in bonuses and share awards.

Evening Standard

AstraZeneca boss Pascal Soriot’s pay rises to £17.7m

Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects

The Guardian - UK

AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment

Pascal Soriot suggests UK-US agreement will not be enough to revive plan to expand Cambridge site

The Guardian - UK

AstraZeneca profits jump by 40% amid strong demand for cancer drugs

Shares edged 1% higher in morning trading on Tuesday, with the stock having risen 28% in the past six months.

Evening Standard

GSK, take two: the bullish tone at the top is finally more convincing

New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Who is on Keir Starmer's China trip, and why are they there?

A delegation of ministers, business leaders and cultural figures are part of the trip, as the Prime Minister seeks to improve relations

The Guardian - UK

NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

Pascal Soriot calls for cost-effectiveness thresholds to undergo ‘substantial adjustment based on inflation’

The Guardian - US

AstraZeneca makes deal with Trump to lower drug prices and avoid tariffs

Company will sell some medicines at a discount to government’s Medicaid health plan in exchange for tariff relief

The Independent UK

AstraZeneca agrees to lower drug prices for Medicaid under Trump administration deal

AstraZeneca has agreed to lower prescription drug costs for Medicaid under a deal with the Trump administration

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

AstraZeneca to upgrade US listing in ‘knock-back for London’

UK’s biggest drugmaker will put its US shares on a par with its London-based stock but says HQ will stay in Cambridge

Evening Standard

AstraZeneca pauses £200m expansion in Cambridge

It comes after the pharmaceutical firm abandoned plans to invest £450 million in a vaccine plant in Merseyside earlier this year.

The Independent UK

Top executives’ pay in UK hits record high – reaching 122 times of average worker

It marks the fourth year in a row that chief executives have taken home a record amount

Evening Standard

Top executive pay in UK’s biggest firms hits new record as more take home £10m

Median pay for chief executive officers of FTSE 100 companies was £4.58 million in the 2024-2025 financial year.

The Guardian - UK

Record salaries for UK chief executives as pay rises for third year in a row

Report finds more than £1bn handed out to just 217 FTSE 100 bosses in the last financial year

The Guardian - UK

Ministers take note: now is the moment to fight to keep AstraZeneca’s listing in London

One hopes cogs are turning in Westminster after Pascal Soriot’s affectionate talk of US at pharmaceutical giant’s half-year results

The Guardian - UK

AstraZeneca chief executive hails ‘vital importance of US’ as Trump tariffs loom

Pascal Soriot refuses to be drawn, however, on reports AZ could move its main stock market listing across the Atlantic

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the London Stock Exchange

200 stories

the Natural History Museum

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.